RT Journal Article
T1 Biomarkers of idiosyncratic drug-induced liver injury (DILI)-a systematic review
A1 Atallah, Edmond
A1 Freixo, Cristiana
A1 Alvarez-Alvarez, Ismael
A1 Cubero, F. J.
A1 Gerbes, Alexander L.
A1 Kullak-Ublick, Gerd A.
A1 Aithal, Guruprasad P.
K1 Drug-induced liver injury
K1 DILI
K1 hepatotoxicity
K1 biomarkers
K1 systematic review
K1 Serum
K1 Microrna-122
K1 Outcomes
K1 Quality
K1 Blood
AB Introduction Idiosyncratic drug-induced liver injury (DILI) is an unpredictable event, and there are no specific biomarkers that can distinguish DILI from alternative explanations or predict its clinical outcomes. Areas covered This systematic review summarizes the available evidence for all biomarkers proposed to have a role in the diagnosis or prognosis of DILI. Following a comprehensive search, we included all types of studies in humans. We included DILI cases based on any threshold criteria but excluded intrinsic DILI, commonly caused by paracetamol overdose. We classified studies into diagnostic and prognostic categories and assessed their methodological quality. After reviewing the literature, 14 studies were eligible. Expert Opinion Diagnostic studies were heterogeneous with regard to the study population and outcomes measured. Prognostic models were developed by integrating novel biomarkers, risk scores, and traditional biomarkers, which increased their prognostic ability to predict death or transplantation by 6 months. This systematic review highlights the case of need for non-genetic biomarkers that distinguish DILI from acute liver injury related to alternative etiology. Biomarkers with the potential to identify serious adverse outcomes from acute DILI should be validated in independent prospective cohorts with a substantial number of cases.
PB Taylor & francis ltd
SN 1742-5255
YR 2021
FD 2021-11-13
LK https://hdl.handle.net/10668/26960
UL https://hdl.handle.net/10668/26960
LA en
DS RISalud
RD Apr 5, 2025